Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study).

Trial Profile

Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study).

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs Exenatide (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EUREXA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Oct 2012 Extension study results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 05 Oct 2012 Results asessing the effects of long-term treatment on markers of cardiovascular risk and bodyweight presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top